310 related articles for article (PubMed ID: 18438404)
1. Activation of the endocannabinoid system by organophosphorus nerve agents.
Nomura DK; Blankman JL; Simon GM; Fujioka K; Issa RS; Ward AM; Cravatt BF; Casida JE
Nat Chem Biol; 2008 Jun; 4(6):373-8. PubMed ID: 18438404
[TBL] [Abstract][Full Text] [Related]
2. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.
Long JZ; Nomura DK; Vann RE; Walentiny DM; Booker L; Jin X; Burston JJ; Sim-Selley LJ; Lichtman AH; Wiley JL; Cravatt BF
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20270-5. PubMed ID: 19918051
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
Kinsey SG; O'Neal ST; Long JZ; Cravatt BF; Lichtman AH
Pharmacol Biochem Behav; 2011 Mar; 98(1):21-7. PubMed ID: 21145341
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
[TBL] [Abstract][Full Text] [Related]
6. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
7. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase.
Burston JJ; Sim-Selley LJ; Harloe JP; Mahadevan A; Razdan RK; Selley DE; Wiley JL
J Pharmacol Exp Ther; 2008 Nov; 327(2):546-53. PubMed ID: 18682568
[TBL] [Abstract][Full Text] [Related]
8. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.
Schlosburg JE; Blankman JL; Long JZ; Nomura DK; Pan B; Kinsey SG; Nguyen PT; Ramesh D; Booker L; Burston JJ; Thomas EA; Selley DE; Sim-Selley LJ; Liu QS; Lichtman AH; Cravatt BF
Nat Neurosci; 2010 Sep; 13(9):1113-9. PubMed ID: 20729846
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB
Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
[TBL] [Abstract][Full Text] [Related]
10. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.
Long JZ; Li W; Booker L; Burston JJ; Kinsey SG; Schlosburg JE; Pavón FJ; Serrano AM; Selley DE; Parsons LH; Lichtman AH; Cravatt BF
Nat Chem Biol; 2009 Jan; 5(1):37-44. PubMed ID: 19029917
[TBL] [Abstract][Full Text] [Related]
11. Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels.
Nomura DK; Hudak CS; Ward AM; Burston JJ; Issa RS; Fisher KJ; Abood ME; Wiley JL; Lichtman AH; Casida JE
Bioorg Med Chem Lett; 2008 Nov; 18(22):5875-8. PubMed ID: 18752948
[TBL] [Abstract][Full Text] [Related]
12. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
[TBL] [Abstract][Full Text] [Related]
13. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.
Clapper JR; Moreno-Sanz G; Russo R; Guijarro A; Vacondio F; Duranti A; Tontini A; Sanchini S; Sciolino NR; Spradley JM; Hohmann AG; Calignano A; Mor M; Tarzia G; Piomelli D
Nat Neurosci; 2010 Oct; 13(10):1265-70. PubMed ID: 20852626
[TBL] [Abstract][Full Text] [Related]
14. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet.
Starowicz KM; Cristino L; Matias I; Capasso R; Racioppi A; Izzo AA; Di Marzo V
Obesity (Silver Spring); 2008 Mar; 16(3):553-65. PubMed ID: 18239598
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
17. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.
Kinsey SG; Long JZ; Cravatt BF; Lichtman AH
J Pain; 2010 Dec; 11(12):1420-8. PubMed ID: 20554481
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
Cravatt BF; Lichtman AH
Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
[TBL] [Abstract][Full Text] [Related]
20. Critical enzymes involved in endocannabinoid metabolism.
Basavarajappa BS
Protein Pept Lett; 2007; 14(3):237-46. PubMed ID: 17346227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
